# Une image contenant Police, capture d’écran, Graphique, noir Description générée automatiquement

# EURÊKA Foundation PhD Project Proposal

EURÊKA Mission statement: The EURÊKA Foundation provides financial support as well as time, guidance and a real commitment to working with several associations. The mission of the Foundation is to help vulnerable people affected by physical and mental health disorders and support research programs on unmet medical needs as well as new treatments. Thus, to avoid too much fundamental scientific research, the EURÊKA Foundation funds PhDs with a 3, 4 or 5 TRL (Technology readiness level).

|  |  |  |  |
| --- | --- | --- | --- |
| Names of the members of the proposed supervisory committee *(Please add as many rows as required)* | | | |
|  | Supervisor Name | Department, University | % Supervision *(e.g. 50:50, 70:15:15)* |
| Lead |  |  |  |
| Second |  |  |  |
| Third |  |  |  |

|  |
| --- |
| Title of project: |

|  |
| --- |
| 5-8 key words: |

|  |
| --- |
| Abstract: (max 250 words) |

|  |
| --- |
| Description of project (max 2 pages): *Please explain:*  *1 – State-of-the-art and rationale behind the project, existing preliminary studies*  *2 – The need for the project, is it part of a bigger one?*  *3 – Objectives of the project*  *4 – Experimental approach (including information on experimental design if appropriate)*  *5 – What will be the involvement of the PhD student in the project, including training, outreach and patient involvement.*  *6 – Which resources available to achieve success (eg sufficient patients for translational or clinically based studies, specific lab equipment)* |

|  |
| --- |
| Host Group (max 250 words) *Please provide a description of the host group detailing why it is the appropriate host for this PhD project. Include information on the future supervisor (career stage, experience in the scientific area and approach to training PhD students).*  *Organization of the hosting lab (flow chart), list all collaborators to the project whether from industry, clinics or academia. Potential industrial engagement in the studentship (e.g. pharma or biotech co-funding of the studentship or in-kind contribution)?* |

|  |
| --- |
| Describe how novel or disruptive your idea is within the current competitive landscape (max 150 words)  *What clinical benefits could your project deliver? (e.g. how realistic is the clinical benefit?)*  *Why is this particular collaboration best placed to train PhD students in this research area?* |

|  |
| --- |
| Risk assessment and mitigation measure (150 words) |

|  |
| --- |
| Resources / Biostatistical considerations (max 150 words) *Do any of the aspects of this project require uncommon resources, e.g. access to patients, patient samples to patient data, unusual, expensive or technically demanding equipment, specific collaborators. Is the applicant guaranteed access to these resources?*  *Please include a detailed biostatistical plan that illustrates that you will have sufficient cases to provide statistical power to support your observations (sample size statistics, e.g. in a xenograft study comparing two parameters how many mice will be studied). Define the nature if statistics employed and relevant power calculations.* |

|  |
| --- |
| Quantitative milestones and feasibility  *Please include the estimated timeline, milestones and deliverables for the execution of this research plan within the grant period (Y1, Y2, Y3) (150 words)* |

|  |
| --- |
| Statement by the candidate (max 500 words) *Please detail why you are interested in this PhD project in particular.*  *Please explain why your experience, career objectives and aptitudes make you well suited to this project.* |

|  |
| --- |
| Candidate c.v. (max 2 pages) |

|  |
| --- |
| Publication plan and Impact |

|  |
| --- |
| Provisional yearly budget |

|  |
| --- |
| Describe the purpose of this work by completing the statement “This grant will be used [to …].” |

## Please send the completed form, along with any additional files, to virginie.faucheur@archimed.group by 26th August 2024 for the 24 September 2024 committee (2pm-4pm)